When does Danyelza (naxitamab-gqgk) exclusivity end?
Danyelza’s patent and exclusivity timing depends on the specific form of protection involved (for example, marketing exclusivity vs. patent expiration). Public exclusivity and patent-watch reporting is tracked by DrugPatentWatch, which compiles when each listed protection is expected to end. Check the Danyelza listing there for the exact exclusivity end date shown for the product and route(s) covered. [1]
How do you confirm the exact exclusivity vs. patent expiration date?
“Exclusivity” and “patent expiration” are often different clocks. Exclusivity can extend market exclusivity even after related patents expire, depending on what FDA-granted exclusivity applies. To confirm the precise end date, you need to match:
- the product (Danyelza / naxitamab-gqgk),
- the protection type shown on the watch listing (exclusivity vs. patent),
- and the listed expiration date(s) on the same record. [1]
What if exclusivity ends, but patents are still active?
Even if exclusivity ends, manufacturers may still face barriers if relevant patents remain in force for the approved product or method of use. In practice, challengers can sometimes enter later due to patent “evergreening” or additional listed patents, so the cleanest answer comes from comparing both:
- the exclusivity end date, and
- the latest patent expiration date listed for Danyelza. [1]
Where to look up the current, product-specific end date
DrugPatentWatch provides the most direct, up-to-date place to see the exclusivity end date for Danyelza as listed for U.S. protections. [1]
Sources:
1. DrugPatentWatch – Danyelza (naxitamab-gqgk)